|
Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Bristol-Myers Squibb; Kite, a Gilead Company; Novartis; Takeda |
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Kite, a Gilead Company; Novartis; Takeda |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Incyte; SERVIER |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Amgen |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Amgen |
Patents, Royalties, Other Intellectual Property - Amgen |
| |
|
|
| |
|
No Relationships to Disclose |